Semiquantitative proteomic analysis of human hippocampal tissues from alzheimer's disease and age-matched control brains

Clinical Proteomics

Volumn 10, Issue 1, 2013, Pages

  Begcevic, Ilijana ^a,b   Kosanam, Hari ^a,b   Martínez Morillo, Eduardo ^a,b   Dimitromanolakis, Apostolos ^b   Diamandis, Phedias ^a   Kuzmanov, Uros ^a,b   Hazrati, Lili Naz ^a,c   Diamandis, Eleftherios P ^a,b,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Hippocampus; Human brain; Mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; BRAIN PROTEIN; PROTEOME;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

EID: 84886541769     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-10-5     Document Type: Article

References (24)

1. Huang Y, Mucke L: Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
2. Ballatore C, Lee VM, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007, 8:663-672. (Pubitemid 47283144)
3. Henry MS, Passmore AP, Todd S, McGuinness B, et al: The development of effective biomarkers for Alzheimer's disease: A review. Int J Geriatr Psychiatry 2013, 28:331-340.
4. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, et al: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995, 38:643-648.
5. Sunderland T, Linker G, Mirza N, Putnam KT, et al: Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Jama 2003, 289:2094-2103. (Pubitemid 37430211)
6. Holtzman DM: CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging 2011, 32(Suppl 1):S4-S9.
7. Hampel H, Burger K, Teipel SJ, Bokde AL, et al: Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008, 4:38-48.
8. Blennow K, Wallin A, Agren H, Spenger C, et al: Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995, 26:231-245. (Pubitemid 26002016)
9. Kohnken R, Buerger K, Zinkowski R, Miller C, et al: Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000, 287:187-190. (Pubitemid 30339380)
10. Mattsson N, Zetterberg H, Blennow K: Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. Int J Alzheimers Dis 2010, 2010:1-5.
11. Albert MS, DeKosky ST, Dickson D, Dubois B, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
12. Korolainen MA, Nyman TA, Aittokallio T, Pirttila T: An update on clinical proteomics in Alzheimer's research. J Neurochem 2010, 112:1386-1414.
13. Zellner M, Veitinger M, Umlauf E: The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathol 2009, 118:181-195.
14. Donovan LE, Higginbotham L, Dammer EB, Gearing M, et al: Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease. Proteomics Clin Appl 2012, 6:201-211.
15. Andreev VP, Petyuk VA, Brewer HM, Karpievitch YV, et al: Label-Free Quantitative LC-MS Proteomics of Alzheimer's Disease and Normally Aged Human Brains. J Proteome Res 2012, 11:3053-3067.
16. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, et al: Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 2007, 11:153-164. (Pubitemid 47010980)
17. Braak H, Braak E: Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991, 1:213-216.
18. Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800. (Pubitemid 34663580)
19. Crecelius A, Gotz A, Arzberger T, Frohlich T, et al: Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-DDIGE. Proteomics 2008, 8:1276-1291. (Pubitemid 351462933)
20. Dickson DW: Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 2004, 114(1):23-27. (Pubitemid 39071640)
21. Di Rosa G, Odrijin T, Nixon RA, Arancio O: Calpain inhibitors: A treatment for Alzheimer's disease. J Mol Neurosci 2002, 19(1-2):135-141. (Pubitemid 35013347)
22. Veeranna, Kaji T, Boland B, Odrljin T, Mohan P, Basavarajappa BS, Peterhoff C, Cataldo A, Rudnicki A, Amin N, Li BS, Pant HC, Hungund BL, Arancio O, Nixon RA: Calpain mediates calcium-induced activation of the erk1, 2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am J Pathol 2004, 165(3):795-805. (Pubitemid 39129287)
23. Schutzer SE, Liu T, Natelson BH, Angel TE, et al: Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010, 5:e10980-e10986.
24. Prassas I, Chrystoja CC, Makawita S, Diamandis EP: Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. BMC Med 2012, 10:39-51.